Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator.

@article{Forestier2007ImprovedOI,
  title={Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator.},
  author={Claire Forestier and Toshiyuki Takaki and Alberto Molano and Jin Seon Im and Ian Baine and Elliot S. Jerud and P. M. Illarionov and Rachel Mwikali Ndonye and Amy R Howell and Pere Santamaria and Gurdyal S Besra and Teresa P DiLorenzo and Steven A Porcelli},
  journal={Journal of immunology},
  year={2007},
  volume={178 3},
  pages={
          1415-25
        }
}
Activation of CD1d-restricted invariant NKT (iNKT) cells by alpha-galactosylceramide (alphaGalCer) significantly suppresses development of diabetes in NOD mice. The mechanisms of this protective effect are complex, involving both Th1 and Th2 cytokines and a network of regulatory cells including tolerogenic dendritic cells. In the current study, we evaluated a newly described synthetic alphaGalCer analog (C20:2) that elicits a Th2-biased cytokine response for its impact on disease progression… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

Role of NKT cells in the digestive system. II. NKT cells and diabetes.

  • American journal of physiology. Gastrointestinal and liver physiology
  • 2007
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED